Pfizer ORAL Start Phase 3 study meets primary endpoint
The ongoing two-year study in methotrexate (MTX)-naïve patients with moderate-to-severe active RA, randomized to receive tofacitinib 5mg or 10mg twice-daily (BID) as monotherapy or MTX, met its primary